Compare FRGT & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRGT | PPCB |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | Mexico | Australia |
| Employees | N/A | 2 |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 1.9M |
| IPO Year | 2021 | N/A |
| Metric | FRGT | PPCB |
|---|---|---|
| Price | $0.88 | $0.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 119.0K | ★ 1.2M |
| Earning Date | 05-20-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,728,922.00 | N/A |
| Revenue This Year | $371.03 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.60 | $0.10 |
| 52 Week High | $3.49 | $10.69 |
| Indicator | FRGT | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 41.14 | 32.39 |
| Support Level | $0.62 | N/A |
| Resistance Level | $1.12 | $0.13 |
| Average True Range (ATR) | 0.09 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 32.86 | 3.33 |
Freight Technologies Inc is a technology company developing solutions to optimize and automate the supply chain process. Along with its subsidiary, Freight App, Inc, the group is focused on making shipping transparent and efficient. Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (OTR) shipping. The company uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.